Is Ampio Pharmaceuticals, Inc. (AMPE) A Good Stock To Buy?

We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the government. The 13F filings show the funds’ and investors’ portfolio positions as of September 30. In this article, we look at what those funds think of Ampio Pharmaceuticals, Inc. (NYSEMKT:AMPE) based on that data.

Ampio Pharmaceuticals shareholders have witnessed a decrease in hedge fund sentiment in recent months. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity, but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Agile Therapeutics Inc (NASDAQ:AGRX), Century Casinos, Inc. (NASDAQ:CNTY), and J Alexander’s Holdings Inc (NYSE:JAX) to gather more data points.

Today there are a multitude of methods investors have at their disposal to assess stocks. Two of the less known methods are hedge fund and insider trading indicators. Our researchers have shown that, historically, those who follow the best picks of the top money managers can beat the broader indices by a superb amount (see the details here).

Keeping this in mind, let’s go over the new action surrounding Ampio Pharmaceuticals, Inc. (NYSEMKT:AMPE).

How have hedgies been trading Ampio Pharmaceuticals, Inc. (NYSEMKT:AMPE)?

Heading into Q4, a total of 5 of the hedge funds tracked by Insider Monkey were long this stock, a change of -44% from the previous quarter. With hedgies’ positions undergoing their usual ebb and flow, there exists an “upper tier” of notable hedge fund managers who were increasing their holdings substantially (or already accumulated large positions).

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Fred Knoll’s Knoll Capital Management has the biggest position in Ampio Pharmaceuticals, Inc. (NYSEMKT:AMPE), worth close to $9.8 million, amounting to 4.2% of its total 13F portfolio. The second largest stake is held by Millennium Management, led by Israel Englander, holding a $0.5 million position; less than 0.1%% of its 13F portfolio is allocated to the stock.